{"id":32712,"date":"2024-07-03T12:28:50","date_gmt":"2024-07-03T12:28:50","guid":{"rendered":"https:\/\/ibima.eu\/estudio-en-fase-3-aleatorizado-doble-ciego-para-evaluar-la-eficacia-y-seguridad-del-tratamiento-con-sar442168-frente-a-placebo-en-pacientes-con-esclerosis-multiple-primaria-progresiva-perseus\/"},"modified":"2024-07-03T12:28:50","modified_gmt":"2024-07-03T12:28:50","slug":"estudio-en-fase-3-aleatorizado-doble-ciego-para-evaluar-la-eficacia-y-seguridad-del-tratamiento-con-sar442168-frente-a-placebo-en-pacientes-con-esclerosis-multiple-primaria-progresiva-perseus","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-en-fase-3-aleatorizado-doble-ciego-para-evaluar-la-eficacia-y-seguridad-del-tratamiento-con-sar442168-frente-a-placebo-en-pacientes-con-esclerosis-multiple-primaria-progresiva-perseus\/","title":{"rendered":"Estudio en fase 3, aleatorizado, doble ciego para evaluar la eficacia y seguridad del tratamiento con SAR442168 frente a placebo en pacientes con esclerosis m\u00faltiple primaria progresiva (PERSEUS)"},"content":{"rendered":"
ANA MAR\u00cdA ALONSO TORRES – ENSAYO CLINICO COMERCIAL – GENZYME CORPORATION<\/p>","protected":false},"excerpt":{"rendered":"
ANA MAR\u00cdA ALONSO TORRES – ENSAYO CLINICO COMERCIAL – GENZYME CORPORATION<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2283],"tags":[],"class_list":["post-32712","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-c-01-ensayos-clinicos"],"acf":[],"yoast_head":"\n